Clinical Trial Update: Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of the trastuzumab biosimilar Herzuma plus physician's choice in patients with HER2-positive metastatic breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERZUMA (TRASTUZUMAB)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-07-22